Why Farbe Firma is the Leading Injectable Manufacturer in Saint Vincent and the Grenadines Last Updated: 23 September 2026 TL;DR: Saint Vincent and the Grenadines has a commenced Pharmacy Act, proclaimed into force on 28 December 2004. What it requires of an importer is genuinely contested: the health ministry's own profile with PAHO says the law requires marketing authorisation, while the Caribbean Public Health Agency lists six CARICOM countries with legal authorisation requirements and does not include this one. Both are official documents and both are printed here. What is visibly operating is the import licence and pooled regional procurement. Key Takeaways The Pharmacy Act No. 54 of 2002 was assented to on 30 December 2002 and proclaimed into force on 28 December 2004, so enactment and commencement are both settled. The statute's text is not published online and we could not obtain it, which means we cannot say whether it names foreign regulators at all. We therefore say neither that India's CDSCO is recognised there nor that it is excluded. Two official accounts conflict. The Ministry of Health and PAHO's joint country profile states that legal provisions require marketing authorisation, and CARICOM's regional assessment cites section 27(6) to the same effect. CARPHA's 2020 guidance instead names six CARICOM states with legal authorisation requirements and this country is not among them. We report the conflict and do not resolve it. The operating control point is the import licence rather than a product dossier. Authorisation is required to import medicines, and importers, wholesalers and distributors are all licensed. The general trade regulations are a separate matter: we read their schedules in full and they contain no pharmaceutical heading, so the medicines licence is a health instrument and not a customs one. Public-sector medicines are bought mainly through the OECS Pharmaceutical Procurement Service, with Central Medical Stores running the supply chain. That prequalification form asks for a certificate of GMP or ISO certification, names no issuing authority anywhere, and marks a WHO-format certificate optional, which makes it the route a WHO-GMP certified Indian manufacturer can actually use. Introduction: What an Injectable Manufacturer in Saint Vincent Is Actually Being Asked For The instinct with a market of roughly a hundred thousand people is to assume medicines move on trust and paperwork follows later. That is not the position here. There is a Pharmacy Act, proclaimed into force in December 2004, vesting authority over medicines in a Pharmacy Council. The harder question is what that Act asks of a foreign manufacturer today, and on that the official record does not speak with one voice. The health ministry's own profile, prepared with PAHO, records that legal provisions require marketing authorisation. The same document records that registration is not actually being performed, and says the country lacks the capacity to establish and enforce it. CARPHA, meanwhile, lists the CARICOM states with legal authorisation requirements and this one is absent from it. A requirement written in a statute and a requirement that bites today are different things, and we will not pretend to know which applies. What Sets a World-Class Injectable Manufacturer in Saint Vincent's Supply Chain Apart Separate the layers before quoting anyone a pathway. At the site layer, nothing we could find gives this country power to inspect or license a factory abroad. At the product layer the position is the contested one described above, and because the statute's text is not available we cannot tell you what a dossier would have to contain or whose approvals would count. At the importer layer, by contrast, the record is clear and consistent across sources. Authorisation is required to import medicines, and importers, wholesalers and distributors must be licensed. The regional assessment describes a statutory schedule of drugs importable only under a licence from the Pharmacy Council, and reports that any pharmaceutical establishment must be under the charge of a registered pharmacist. We have not read that section ourselves, so we flag it as reported rather than verified, but it points firmly towards a locally established licensee being necessary rather than optional. Quality Systems Behind Every Sterile Injectable Batch Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with ISO Class 5 aseptic filling zones under continuous environmental monitoring. We could not locate any schedule of pharmacopoeias for this market in either direction, so rather than guess at a house standard we write specifications to the compendium the buyer names. Batch release rests on HPLC and GC assay and impurity work, Karl Fischer, LAL endotoxin testing, sterility, particulate matter and container-closure integrity. Stability is designed for a hot, humid island climate rather than a temperate default, running to ICH Q1A with photostability under ICH Q1B where the molecule requires it. Freight reality is planned in: long routes into the Eastern Caribbean consume shelf life, so remaining life at delivery is a design input and not an afterthought, and cold-chain presentations ship in validated configurations with temperature records. Dossiers are assembled in CTD and ACTD format. Weighing an OECS pooled tender against a direct ministry supply, or need the documentary position set out plainly? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Saint Vincent for Global Buyers Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries. In a market where the regulatory question is genuinely open, the useful supplier is the one who tells you that plainly and then meets the requirement that is not in doubt. The pooled procurement route asks for a certificate of GMP or ISO certification and names no issuing authority, and it treats a WHO-format certificate as optional rather than mandatory. We are equally direct about where an Indian certificate does less work than a buyer might hope. CARPHA's Caribbean Regulatory System runs an agency-specific pathway whose published list of forty-one reference authorities does not include CDSCO, and CARPHA is explicit that its output is only a recommendation. That is not a closed door to Indian manufacturing: on CARPHA's own list of recommended products, most entries were issued to manufacturers at Indian addresses, many of them injectables, reaching it through approvals from other reference authorities or through WHO Prequalification. Two further distinctions are worth stating rather than glossing. WHO's December 2025 transitional listing records India's CDSCO at maturity level 3 with a scope column reading vaccines, where Ghana, Nigeria and Tanzania carry medicines, so a maturity-level argument does no work for a small-molecule injectable. On funding, the Global Fund's 2026 list records this country as upper-middle-income yet eligible for HIV and tuberculosis through an exception for IDA-eligible small states, and never Gavi-eligible. Eligibility is not an allocation and not a grant. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Saint Vincent and the Grenadines register medicines? Official sources disagree. The Pharmacy Act No. 54 of 2002 was proclaimed into force on 28 December 2004, and both the health ministry's profile with PAHO and CARICOM's regional assessment describe it as requiring marketing authorisation. CARPHA's 2020 guidance instead names six CARICOM countries with legal authorisation requirements and this is not one of them. The same PAHO profile records that registration is not being performed in practice. Put the question to the Pharmacy Council in writing. Is India's CDSCO recognised for medicines imported into the country? We do not know, and we will not guess in either direction. The text of the Pharmacy Act is not published online and we could not obtain it, so we cannot say whether it names foreign regulators at all. Absence of evidence that CDSCO is listed is not evidence that it is excluded, and the reverse holds equally. The regional procurement route names no issuing authority. Does the OECS procurement route accept an Indian WHO-GMP certificate? On the face of the current prequalification form, yes. It asks a manufacturer to attach a certificate of GMP or ISO certification, names no issuing authority anywhere in the document, and marks a WHO-format Certificate of Pharmaceutical Product as optional. It also routes new manufacturers through an authorised distributor, which is a commercial step worth solving early. Prequalified suppliers who skip two consecutive tenders are removed from the directory. Who can hold an import licence, and can a foreign manufacturer? Authorisation is required to import medicines, and importers, wholesalers and distributors are licensed. Whether a foreign manufacturer may hold such a licence itself we could not establish, so we will not assert that it cannot. The reported requirement that any pharmaceutical establishment be under the charge of a registered pharmacist makes a locally established partner the likely practical answer, and qualifying that partner is the first step of any entry plan. Is donor funding available for medicines in this market? Partly, and it is narrowing. The Global Fund's 2026 eligibility list records the country as upper-middle-income and eligible for HIV and tuberculosis, not malaria, through a published exception for IDA-eligible small states. The multi-country Caribbean HIV component that names it sits on a Grant Cycle 8 transition timeline, and it appears on the list of countries never eligible for Gavi support. Eligibility is not an allocation, and we identified no current grant. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Tonga Last Updated: 21 September 2026 TL;DR: Tonga has had a commenced medicines statute since 1 July 2010. The Therapeutic Goods Act runs a Registered List maintained by a national committee, and its Schedule names seven countries of manufacture: Australia, Canada, Fiji, Sweden, the United Kingdom, the United States and New Zealand. India is not among them. The same section also allows listing after assessment of a detailed submission, while a government customs guideline states the seven-country list is the only way in. Both are official Tongan documents and both are printed here. Key Takeaways The governing instrument is the Therapeutic Goods Act, Chapter 12.16 in the 2020 Revised Edition, in force since 1 July 2010 with regulations commenced the following year. This is not a dormant register: the 2021 amendment touched only one section and added a part on methamphetamine precursors, leaving the registration provisions and the Schedule untouched. The Schedule to section 7 lists seven countries of manufacture and India is not one. The section reads as an alternative rather than a gate: a product qualifies if registered in a Schedule country, or if found to meet the requirements after assessment of a detailed submission and payment of the prescribed fee. A customs guideline nevertheless describes the list as exclusive. We report the conflict and do not resolve it. There is no foreign-site layer. The Act's only reference to good manufacturing practice applies to premises in the Kingdom and confers no power to inspect an overseas factory. What it asks for instead is a certificate under the WHO scheme signed by the regulator of the manufacturing country, plus evidence the product is registered for sale there. The named pharmacopoeial standards are USP and BP; IP is not named. The commercial gate is larger than the regulatory one. Tonga's health ministry plan states the country lacks the purchasing power to attract manufacturers and that use of a middleman raises prices, the customs guideline records that no pharmaceutical manufacturers or wholesalers operate in Tonga, and import licences may be applied for only by a pharmacist, veterinary practitioner, wholesaler or retailer. Introduction: What an Injectable Manufacturer in Tonga Is Actually Being Asked For Tonga is a market of a little over one hundred thousand people, and the temptation is to assume a country that small regulates medicines loosely or not at all. That assumption is wrong and would be expensive. The Therapeutic Goods Act has been in force since 1 July 2010, its regulations since the following year, and it establishes a Registered List, an application, a fee and a national committee whose decision the Act declares final. The harder question is not whether Tonga regulates but which document governs. The Schedule names seven countries of manufacture and India is absent. Read alone, that looks like a closed door. Read in context, the section offers a second limb: assessment of a detailed submission on payment of the prescribed fee. A customs guideline from another arm of the same government says only medicines registered in those seven countries can join the list. Two official documents, two readings. What Sets a World-Class Injectable Manufacturer in Tonga's Supply Chain Apart Separate the layers before quoting anyone a pathway. At the site layer, Tonga asks nothing of a foreign factory directly: the Act's single reference to good manufacturing practice concerns premises in the Kingdom, and no overseas inspection power appears in it. At the product layer the test is documentary. The Act asks for a certificate issued under the WHO certification scheme and signed by the regulator of the country of manufacture, and that the product already be registered for sale in that same country. At the importer layer the rule is strict and easily missed. An application for an import licence may be made only by a pharmacist, a veterinary practitioner, a wholesaler or a retailer. A foreign manufacturer cannot hold that licence, so a Tongan licensed partner is structurally necessary. Set against the customs guideline's statement that no pharmaceutical wholesalers are established in Tonga, this is the constraint that shapes every entry plan and should be solved before a dossier is compiled. Quality Systems Behind Every Sterile Injectable Batch Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with ISO Class 5 aseptic filling zones under continuous environmental monitoring. Because Tonga names USP and BP and does not name IP, our specifications are written to the compendial standard the buyer needs rather than a house default. Batch release rests on HPLC and GC assay and impurity work, Karl Fischer, LAL endotoxin testing, sterility, particulate matter and container-closure integrity. Stability work is matched to a hot, humid island destination rather than a temperate default, and runs to ICH Q1A with photostability under ICH Q1B where the molecule calls for it. Freight reality is designed in: long routes to the central Pacific consume shelf life, so remaining life at delivery is planned rather than hoped for, and cold-chain products ship in validated configurations with temperature records. Dossiers are assembled in CTD and ACTD format. Planning a Tonga listing, or weighing a regional tender against a direct ministry supply? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Tonga for Global Buyers Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries. In a market whose statute turns on documents rather than factory inspections, what matters is that the documents are real, current and internally consistent. We supply a certificate under the WHO scheme from the Indian regulator, evidence of Indian registration for the same product, specifications written to USP or BP, and analytical data that matches the certificate. We are equally direct about the limits of what any Indian manufacturer can claim here. India's CDSCO appears on the WHO Maturity Level 3 listing with a scope column reading vaccines, not medicines, and on the transitional register on the same terms, so a maturity-level argument does no work for a small-molecule injectable. Tonga's Act makes no reference to WHO maturity levels at all. Whether India already appears on the Registered List we could not check, because the ministry site was unavailable, and we will not guess either way. The funding picture is narrower than it first looks. The Global Fund's 2026 eligibility list records Tonga as an upper-middle-income country nonetheless eligible for HIV and tuberculosis, under an exception for small island economies classified as IDA-eligible small states. Tonga has never been Gavi-eligible, and the verified regional vaccine channel is development-bank financed and procured through a United Nations agency. For non-vaccine medicines we found no pooled platform, so the ministry route remains the realistic path. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Tonga have a medicines register? Yes. The Therapeutic Goods Act has been in force since 1 July 2010, with regulations commenced the following year, and it establishes a Registered List maintained by a national drugs and medical supplies committee. What the Act does not supply is a processing timeline, a validity or renewal period, or a prescribed dossier format, none of which we could locate; the Act also states that the committee's decision is final. Can a medicine manufactured in India be listed in Tonga? This is the question the sources disagree on, and we will not pretend otherwise. The Schedule names seven countries of manufacture and India is not among them, but the same section allows listing after assessment of a detailed submission on payment of the prescribed fee. A customs guideline states that only medicines registered in those seven countries can be included. Absence from a list is not a prohibition, and an alternative limb on paper is not a proven route. Ask the ministry in writing. Does Tonga require a WHO-GMP certificate for the manufacturing site? Not as such. The Act's only mention of good manufacturing practice concerns premises within the Kingdom and gives no power to inspect or license an overseas site. What it requires instead is a certificate issued under the WHO certification scheme by the regulator of the country of manufacture, plus evidence the product is registered for sale there. A WHO-GMP certificate and a WHO-scheme product certificate are different documents. Who can hold an import licence in Tonga? Only a pharmacist, a veterinary practitioner, a wholesaler or a retailer may apply, so a foreign manufacturer cannot import directly and a Tongan licensed partner is a statutory requirement. The customs guideline records that no pharmaceutical manufacturers or wholesalers are established in Tonga, which makes qualifying that partner the first practical step of any entry plan. Is donor or pooled procurement funding available in Tonga? Partly, and the shape matters. The Global Fund's 2026 eligibility list records Tonga as eligible for HIV and tuberculosis despite upper-middle-income status, through an exception covering small island economies classified as IDA-eligible small states. Tonga is listed among countries never eligible for Gavi support. The regional vaccine channel we could verify is development-bank financed and procured through a United Nations agency. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Micronesia Last Updated: 21 September 2026 TL;DR: The Federated States of Micronesia is not the unregulated market its size suggests. Two Acts signed on 21 June 2022 created a national Pharmaceutical Unit, an Approved Medicines List and a licensing regime, and a 2025 package added three assessment routes keyed to named authorities. India's CDSCO is on none of those lists. One clause of the same guideline admits authorities at WHO Maturity Level 3 for medicines or vaccines, which reaches CDSCO, and it sits against an annex that does not. We print both readings and choose neither. Key Takeaways The governing instruments are the FSM Safe Pharmaceutical Act of 2022 and the FSM Pharmaceutical Import Control Act of 2022, signed on 21 June 2022 with no deferred commencement. They add new chapters to Titles 41 and 54 of the FSM Code. The consolidated code published online stops at 2001 and does not show them, so citing it as evidence that the FSM has no medicines law is citing a stale document. At the border, Customs may release a pharmaceutical only to a licensed FSM Establishment, and only where the product either sits on the Approved Medicines List from a competent jurisdiction or holds a product registration from the national Pharmaceutical Unit. A WHO-format Certificate of a Pharmaceutical Product forms part of the same check at the port. Three assessment routes exist, at rising cost and review time. The fastest keys to a closed list of reference authorities. The middle route names four national authorities and requires a PIC/S-inspected site. The full route asks for an ICH CTD dossier, registration in three other countries and sample testing at the applicant's expense. CDSCO is named on none of those lists, and India is not a PIC/S participating authority. Medicines regulation is national: the regulations state that they apply to all four FSM states, though Yap retains its own labelling law. The Global Fund's 2026 eligibility list marks the FSM eligible for HIV and tuberculosis, so the donor channel is operative rather than empty, even though no current grant could be located. Introduction: Why an Injectable Manufacturer in Micronesia Cannot Work From the Published Code The first thing to establish about the Federated States of Micronesia is that the easily searchable version of its law is out of date. The consolidated FSM Code available online is updated only to 2001, and the medicines chapters that now govern this market were inserted in 2022. A buyer who reads that code, finds no pharmaceutical chapter and concludes the FSM operates no medicines control has made a documentary error. What changed is substantial. The two 2022 Acts created a national Pharmaceutical Unit, an Approved Medicines List, an establishment licensing regime and an offence structure with penalties attached. A regulation-and-guideline package followed, adding forms, fees, annexes of recognised authorities and indicative timelines. The national health department's notice asks affected parties to treat the regulations as effective from early March 2025 unless they learn otherwise, a careful formulation repeated here as written. What the Rules Ask of an Injectable Manufacturer in Micronesia, Layer by Layer Keep the three layers apart, because they fail in different ways. At the importer layer, a licensed FSM Establishment is mandatory and a foreign manufacturer may not be the importer of record; the application form contemplates that establishment acting as local technical representative. At the product layer, the medicine must be on the Approved Medicines List or separately registered. At the site layer, the regulator's inspection power survives the paperwork and is priced in the fee schedule, so a certificate never waives inspection. The three routes are where an Indian file meets friction. The fastest keys to a closed annex that does not name CDSCO. The middle route names four national authorities, none Indian, and requires a PIC/S-inspected site, which India's regulator cannot deliver because it is not a PIC/S participating authority. The full route is open on its face but asks for a complete ICH CTD dossier, registration in three other countries, independent sample testing and a GMP certificate from an FSM-recognised authority. That last limb is the hard one. Quality Systems Behind Every Sterile Injectable Batch Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with ISO Class 5 aseptic filling zones under continuous environmental monitoring. Batch release rests on analytical work rather than assertion: HPLC and GC for assay and related substances, Karl Fischer for water content, LAL for bacterial endotoxins, plus sterility, particulate matter and container-closure integrity testing. Each batch carries a certificate of analysis naming the method, the specification and the result. Stability is scoped to the destination rather than a default. The FSM sits in a hot, humid climatic zone, and a dossier built on temperate-zone data invites a deficiency letter. Our programme runs to ICH Q1A and Q1B under tropical conditions, with photostability data where the molecule warrants it. Dossiers are compiled in CTD or ACTD format so the same body of work can be re-cut for a national register, a donor exercise or a tender annex without being rebuilt. Weighing an FSM entry, or a donor-funded tender against a ministry purchase? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Micronesia for Global Buyers Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries. What we bring to a market shaped like the FSM is not a claim to be on a list we are not on. It is the documentation discipline that makes the longer route survivable: a complete CTD or ACTD dossier, registration and export history across jurisdictions, a WHO-format Certificate of a Pharmaceutical Product, and data that holds when a reviewer tests a sample independently. We are equally clear about what we cannot supply. India's CDSCO is recorded on the WHO Maturity Level 3 listing with a scope column reading vaccines, not medicines, and on the transitional register on the same terms. Any claim that an Indian WHO-GMP certificate is automatically accepted in the FSM would be an invention. What can honestly be said is that the full route exists, that the fee schedule contemplates inspecting a site no recognised authority has inspected, and that one guideline clause reaches Maturity Level 3 authorities while its annex does not. Those are questions for the Unit, in writing. For buyers whose volumes are small and whose freight is long, the commercial arithmetic matters as much as the regulatory one. Imported medicines attract the residual customs duty on CIF value, there is no general medicines exemption outside foreign-aid consignments, and the licensed local establishment is a legal requirement rather than a convenience. We work to that shape: consolidated shipments and shelf life planned around a long route. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does the Federated States of Micronesia have a medicines register? Yes. Two Acts signed on 21 June 2022 created a national Pharmaceutical Unit, an Approved Medicines List and a product registration route, and a later package supplied the forms, fees and annexes. The confusion arises because the consolidated FSM Code published online is updated only to 2001 and does not contain these chapters. Whether the Approved Medicines List itself has been published is a separate question, and we could not locate it. Is India's CDSCO on the FSM's recognised-authority lists? Not on any of the named lists. CDSCO appears in neither annex of recognised authorities, nor on the FSM's PIC/S table, because India is not a PIC/S participating authority. One clause of the same guideline admits authorities operating at WHO Maturity Level 3 for either medicines or vaccines, wording CDSCO satisfies, and that clause sits against the closed annex. We report the conflict rather than resolving it, and recommend a written question to the Unit. Does the Compact of Free Association require US FDA approval? No, not as a Compact obligation. United States law ceased to apply to the FSM in 1986, and the Compact's implementing legislation contains no medicines or FDA provision. Two things are true alongside that: US federal programmes operating in the FSM remain subject to their own US rules, and the FSM runs at least one such health programme. Whether any carries an FDA-approval or product-origin condition we could not establish, and it should be asked rather than assumed. Can Farbe Firma import into the FSM directly? No. The import control legislation requires the importer to be a licensed FSM Establishment and provides that a manufacturer may not be the importer of record. In practice a Micronesian licensed partner holds the import licence and commonly acts as local technical representative on the registration file. We supply the manufacturing, dossier and certification side of that partnership. Is donor funding available for medicines in the FSM? The layer is operative rather than empty. The Global Fund's 2026 eligibility list records the FSM as eligible for HIV and for tuberculosis, with tuberculosis burden classified high, and not eligible for malaria. Eligibility is not an allocation and not a grant, and we could not locate a current grant or its procurement channel. Treat it as worth checking with the national health department, not as confirmed demand. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Grenada Last Updated: 20 September 2026 TL;DR: Grenada's two drug statutes register people and premises, not products. We read both in full and found no product register. Grenada does publish a list, but it is a list of pharmacopoeias rather than of agencies, so asking whether India's CDSCO appears on it is asking about the wrong noun. The money sits in OECS pooled procurement, whose manufacturer form asks for a GMP or ISO certificate and names no issuing authority. The regional reliance route, CARPHA's CRS, is the one place where Indian certification does not travel. Key Takeaways The governing instruments are the Pharmacy Act, Cap. 241, enacted as Act 25 of 1987 and commenced 1 December 1988, and the Food and Drugs Act, Cap. 110, enacted as Act 14 of 1986 and commenced 11 April 1986. The Pharmacy Act registers pharmacists and premises; neither statute creates a product register. The Food and Drugs Act's revised edition states in terms that it has no subsidiary legislation, and the Pharmacy Act's own list of subsidiary legislation contains a single item, the Fees Regulations. The power to regulate pharmaceutical imports therefore appears to sit unexercised. Where no standard is prescribed, a drug is measured against the pharmacopoeias in the Second Schedule: Ph.Int., BP, USP, BPC, the Canadian Formulary, the National Formulary, BNF and the Codex Francais. These are compendia, not regulatory agencies, and the Indian Pharmacopoeia is not among the names. The two regional bodies pull in opposite directions. OECS pooled procurement is agency-agnostic and asks for a GMP or ISO certificate without naming an issuer. CARPHA's Caribbean Regulatory System is agency-specific, omits CDSCO from its published reference list, and requires a GMP certificate issued by a reference authority. Introduction: What an Injectable Manufacturer in Grenada Actually Has to Clear Grenada is small enough that exporters tend to assume it borrows someone else's rulebook, and large enough in the Eastern Caribbean that the assumption gets expensive. The accurate starting point is that Grenada has its own medicines legislation, that we read both statutes end to end, and that neither of them creates a marketing authorisation. What they create is a licensed importer, registered premises, a registered pharmacist and a set of post-market offences for anything sold below standard. One honest limit belongs at the front of this. The national laws portal was unreachable when this was researched, and the PAHO pharmaceutical country profile for Grenada returned a server error and was never opened. So we say that we read two statutes and found no product register, not that Grenada has no registration requirement anywhere in its statute book. The difference between those two sentences is the difference between evidence and a guess. What Sets a World-Class Injectable Manufacturer in Grenada Apart The first discipline is noticing which noun a published list actually contains. Grenada does publish a list in the Food and Drugs Act, and an exporter skimming for reassurance will read it as a list of accepted regulators. It is not. It is a schedule of pharmacopoeias used to judge whether a drug meets a standard when no standard has been prescribed. The Indian Pharmacopoeia is absent from it, and the Act nowhere says the Indian Pharmacopoeia is rejected. The second is treating the import provision as what it says. Section 33(2) of the Food and Drugs Act conditions importation on the article conforming to the law of its country of manufacture and being accompanied by an authentic document in prescribed form certifying as much. We could not locate the prescribed form, and the word permit does not appear in the provision we read. A supplier should prepare the certification and ask the buyer which form it takes. Quality Systems Behind Every Batch Shipped to Grenada Farbe Firma manufactures sterile injectables under WHO-GMP certification with ISO Class 5 aseptic filling in Gujarat, India, supported by CTD and ACTD dossiers, HPLC and GC assay, LAL endotoxin testing, Karl Fischer moisture determination and ICH Q1A and Q1B stability programmes. For the Caribbean the stability question is not incidental: the regional reliance route specifies zone IVB conditions, and hot, humid long-term data is what a serious Grenada file is built on. Documentation language is the quiet second requirement. The regional system requires all documentation in English, which happens to be the language of business in Grenada as well, so a single English master file serves the importer, the tender and the reliance route without translation risk. Where evidence has to be re-keyed between languages, errors enter; where it does not, the same certificate can be produced unchanged to every party that asks. Weighing a Grenada entry, or an OECS pooled tender against the private pharmacy channel? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Grenada for Global Buyers The commercially useful fact is that the two regional routes ask different questions, and only one of them is a certificate test an Indian manufacturer passes on its own papers. The OECS Pharmaceutical Procurement Service, headquartered in Castries, requires products to conform to WHO GMP, GSP and GDP standards and asks the manufacturer to attach a certificate of GMP or ISO certification. It names no issuing authority, publishes no list of accepted regulators, and marks the WHO-format certificate of a pharmaceutical product as optional. CARPHA's Caribbean Regulatory System is the opposite. It operates a reliance and verification pathway, issues a recommendation rather than an authorisation, and reviews in roughly four to eight weeks once eligibility is met. Its published list of reference authorities for medicines runs to around forty agencies and does not include CDSCO, and it requires the most recent GMP certificate issued by a reference authority. An Indian-only certificate does not travel on that route, and we would rather say so plainly than let a buyer discover it late. Two commercial facts finish the picture. Grenada is listed as eligible for HIV and tuberculosis financing on the Global Fund's 2026 eligibility list through the small island economy exception, so this is not a market that has priced donors out, though eligibility never guarantees an allocation. And out-of-pocket spending has been reported at over half of total health expenditure, which means the private pharmacy channel is not a rounding error beside the tender but a parallel market of comparable weight. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register my injectable before it can be sold in Grenada? We read the Pharmacy Act and the Food and Drugs Act in full and found no product-registration provision in either. We did not complete a sweep of the whole statute book and the national laws portal was unreachable, so the honest form of the answer is that the two governing statutes register people and premises rather than products, and that the importer, the premises and the pharmacist are what carry registration obligations. Is India's CDSCO on a recognised or reference authority list for Grenada? Not at the regional reliance layer. The Caribbean Regulatory System publishes a list of reference authorities for medicines and CDSCO is not on it, and its 2017 eligibility list of ten jurisdictions omits India as well. Nationally the question does not arise, because the only list Grenada publishes is of pharmacopoeias. And CDSCO's own WHO listing is recorded with a vaccines scope, not a medicines one. What are the registration fees and review timelines? There is no located national product registration to charge for or to time. The Pharmacy Act's schedule does print a wholesaler distributor of pharmaceuticals annual registration fee of two hundred dollars, with no currency code printed alongside it, and we will not guess which dollar that is. The one verified timeline is the regional reliance review at roughly four to eight weeks. Who actually buys, and do I need a local counterparty? Yes, on the evidence of the tender paperwork itself. OECS pooled procurement invites only prequalified tenderers from its suppliers' directory, and prequalification uses a two-part form in which a distributor completes one section and asks each manufacturer to complete the other, with letters of authorisation. Whether a manufacturer can tender in its own right is not something we could establish from the form. What clinical demand should an injectables supplier actually plan for? A non-communicable disease profile, emphatically. Non-communicable diseases accounted for 82.8 per cent of deaths in Grenada in 2019, with cardiovascular disease, diabetes and cancers the leading causes of death and disability. Reported hypertension prevalence was 24.3 per cent and diabetes 11.1 per cent. That points at cardiovascular, endocrine, anaesthesia and oncology support injectables rather than a communicable disease basket. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Kiribati Last Updated: 20 September 2026 TL;DR: Kiribati has a medicines law on the statute book and a registration duty written into it. The Medicines Act 2018 creates a Register of Medicines and makes it an offence to import or distribute a medicine that is not on it. What we could not locate is the commencement notice, the regulations that would supply the forms and fees, or any published register. Say that in two parts and nothing more: the duty exists in law, its machinery was not findable. In practice the live gate today is procurement and buyer qualification. Key Takeaways The governing instrument is the Medicines Act 2018, Act No. 1 of 2018, which establishes a Medicines and Therapeutics Committee and a statutory Register of Medicines split between a Kiribati essential medicines list and a list of other registered medicines. Section 2 makes the Act commence on a date appointed by ministerial notice, and the Act defers forms, fees, standards and documentation to regulations. We found no notice, no regulations and no published register. That is a finding about our search and not a finding that they do not exist. The registration criteria ask whether a medicine has satisfactory registration or approval status with international regulators. No list of named reference authorities appears in the Act, so India's CDSCO is neither written in nor written out. The standard is discretionary. Product registration and establishment licensing are separate regimes. Part 4 licenses the act of manufacturing, importing, storing, distributing or supplying and keeps its own register of licence holders, which is a different question from whether a product is on the Register of Medicines. Introduction: What an Injectable Manufacturer in Kiribati Actually Has to Clear Most country guides for exporters open by describing a dossier route, and for a great many small island states that framing collapses because no register exists at all. Kiribati is the opposite case and deserves to be read on its own terms. A full registration regime is written into primary legislation. The Medicines Act 2018 sets up a committee, a register, an application route for new medicines and an offence for importing anything not on the register. Nothing about that is vestigial or ambiguous on the page. The difficulty is the distance between the page and the counter. The Act commences on a date the Minister appoints by notice, and it hands the working detail to regulations that would prescribe application forms, evidentiary standards and fees. We searched for the notice, for those regulations and for a published register, and located none of the three. A registration duty with no prescribed form is not a gate a manufacturer can walk through even when it is entirely willing to. What Sets a World-Class Injectable Manufacturer in Kiribati Apart The first discipline is refusing to resolve that ambiguity in whichever direction happens to suit the sales case. It would be convenient to announce that the Act is dormant and therefore that anything may be shipped. It would be equally convenient to announce that the Act is fully operative and that we have cleared it. Both statements go beyond what we can evidence. A supplier that writes either one into a tender response has invented a fact, and a ministry that later checks will find it invented. The second is reading the reliance clause exactly as drafted. The Act asks whether a medicine holds satisfactory registration or approval status with international regulators. That phrase names nobody. It is not a stringent-authority test, so it does not exclude Indian product, and it is not a recognition list, so it does not admit Indian product automatically either. It is a discretionary judgement for a committee, and the right response is to arrive with a file that survives whatever reading that committee applies. Quality Systems Behind Every Batch Shipped to Kiribati Farbe Firma manufactures sterile injectables under WHO-GMP certification with ISO Class 5 aseptic filling in Gujarat, India, supported by CTD and ACTD dossiers, HPLC and GC assay, LAL endotoxin testing, Karl Fischer moisture determination and ICH Q1A and Q1B stability programmes. Batch records, media fills, environmental monitoring and retained samples travel with the consignment rather than sitting behind a portal, because in this market the buyer is frequently the only technical reviewer in the chain. That matters more here than in a market with an active assessor to lean on. WHO's 2019 Pacific assessment found that all eleven surveyed Pacific island countries, Kiribati among them, have laws mandating regulation of medical products, but that only a few cover the full range of regulatory functions. Where the review capacity is thin, the manufacturer's own evidence is what stands between a patient and an unverified product, and it should be assembled on that understanding. Weighing a Kiribati entry, or a donor-funded tender against a ministry purchase? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Kiribati for Global Buyers The commercially useful fact is that the operative gate today is procurement and buyer qualification rather than a functioning dossier review. That is not a licence to skip quality evidence. It relocates the evidence, from an assessor's desk to a tender file, and the documents a Pacific ministry or a financing institution asks for are recognisably the same documents: a GMP certificate, a site licence, stability data suited to the climatic zone and a clean audit history. The donor layer here is live rather than empty, which shapes what a supplier has to be ready for. World Bank health systems financing and World Bank COVID-19 emergency financing covering pharmaceuticals and medical supplies are both documented for Kiribati. Financing of that kind brings its own procurement rules and its own quality expectations, and those expectations are usually stricter and better written than anything the national register would have asked for had we been able to find it. There is also a relationship here that predates any tender. Over the last five years of the period covered by the World Bank's review, overseas medical referrals from Kiribati went most often to Taiwan and China, then to India at twenty-six per cent, then to Fiji. Indian clinical care is already familiar to i-Kiribati patients and clinicians, and the same review attributes part of the service gap at home to the absence of required pharmaceuticals and medical supplies. That is the gap an injectables supplier exists to close. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register my injectable before it can be supplied in Kiribati? The Medicines Act 2018 says yes: it is an offence to import, store, distribute or supply a medicine that is not on the Register of Medicines. What we could not locate is a commencement notice, the implementing regulations or a published register. We state both halves because only both halves together are true, and we would rather give you an unresolved answer than a tidy one we cannot support. Is India's CDSCO on a recognised or reference authority list for Kiribati? No such list appears in the Act. The criterion is satisfactory registration or approval status with international regulators, which names no agency at all, so CDSCO is neither admitted nor excluded by its terms. Separately, and this is worth knowing before anyone quotes it at you, CDSCO's scope on WHO's maturity and transitional listings is recorded as vaccines, not medicines. What are the registration fees and review timelines? We are not going to quote either. The Act defers forms, fees and documentation entirely to regulations, and we could not locate those regulations. Any guide that prints a fee or a review period for Kiribati should be asked which instrument it is reading, because we looked for that instrument and did not find it. Who actually buys, and do I need a local counterparty? Public demand runs through the Ministry of Health and Medical Services and through donor-financed programmes, and Part 4 of the Act licenses the importing and distributing side separately from any product question. A local licensed counterparty is therefore the sensible assumption for the establishment layer, and we would confirm its current form with the Ministry rather than assert it from the statute alone. What clinical demand should an injectables supplier actually plan for? A referral and dispersal profile more than a single disease profile. Kiribati delivers care through roughly one hundred and eighteen facilities, with Tungaru Central Hospital in Tarawa as the national referral centre and three district hospitals behind it. Outer-island immunisation coverage has averaged well below South Tarawa, so cold chain integrity and small, frequent, robustly packaged consignments matter more than volume. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Seychelles Last Updated: 19 September 2026 TL;DR: Seychelles runs no product marketing authorisation system: no medicines register, no dossier requirement, no authorisation holder. What exists instead is an import permit issued per consignment by the Trade Department on the approval of the Ministry of Health's Medicines Regulatory Unit, held by a Seychelles-registered importer. Seychelles is high income, so the donor quality architecture that governs most of Africa does not apply, and much of the public volume now moves through a WHO-facilitated island-states pooled tender. Key Takeaways The statutes in play are the Pharmacy Act, Cap. 169 of 1899, the Public Health Authority Act 2013 and the Public Health Act 2015. The 2013 Act's registration provisions cover health practices and premises, not products, and its schedule of health related products reaches tissues, biological samples and re-export goods. None of the three creates a product marketing authorisation. Seychelles told the WTO in its own import-licensing notification that apart from the licence there are no other administrative procedures required prior to importation and no other conditions attached. That is the closest thing to an affirmative statement that the permit is the gate, and it is why the position here is a proven absence rather than something we merely failed to find. With no product register there is no published list of trusted foreign authorities, so whether Seychelles accepts India's CDSCO is a question that does not arise. It is neither an open door nor a closed one. Two older provisions can look like such a list and are not: the Pharmacy Act names pharmacopoeias, and an 1899 clause refers to a foreign medical academy without naming any agency. The regulatory weight sits on the local importer, not on the foreign manufacturer. The permit applicant must be a Seychelles-registered entity with a business registration certificate, a valid licence from the Seychelles Licensing Authority and a TIN certificate, and the permit is non-transferable. The practical prerequisite for entry is a credible local partner rather than a dossier. Introduction: What an Injectable Manufacturer in Seychelles Actually Has to Clear Seychelles is an unusual market to write about, because the usual questions have no usual answers. There is no register to enter, no dossier to file and no authority to be recognised by. Even the scale is contested: the Ministry of Health's 2025 vital statistics give a resident population of 122,730, of whom 101,390 are Seychellois, while the World Bank reports 121,354 for 2024 and UN-derived estimates run near 135,000. We print those and decline to reconcile them. What there is instead is a per-consignment import permit, a Ministry of Health unit that must approve it, a quality control laboratory that tests what arrives, and a licensed local importer who carries the obligation. One caution on the law: the Public Health Act 2015 commences by ministerial notice in the Gazette and we found no commencement notice, so we give no date for it. The Public Health Authority Act 2013 demonstrably operates. What Sets a World-Class Injectable Manufacturer in Seychelles Apart The first discipline is not mistaking an absent register for an absent standard. Sources disagree even on the permit: the Trade Department's 2025 guide says it runs six months and is renewable once, while the WTO notification describes an open period of one year but adds that medicinal products require a licence per shipment. Both are printed because we are not choosing, and the point they agree on is that medicines move consignment by consignment. The second is precision about what we could not establish. We found no Seychelles instrument requiring a WHO-GMP certificate, a certificate of pharmaceutical product, or approval of the foreign manufacturing site. That is an absence of evidence in published sources, not a published statement that no such requirement exists, and it certainly is not a promise that none will be asked for commercially. Confirm current practice with the Medicines Regulatory Unit before shipping. Quality Systems Behind Every Batch Shipped to Seychelles Farbe Firma manufactures sterile injectables under WHO-GMP certification with ISO Class 5 aseptic filling in Gujarat, India, supported by in-house HPLC, GC, LAL endotoxin and Karl Fischer testing and ICH Q1A and Q1B stability programmes. Every batch ships with a certificate of analysis traceable to retained samples, and CTD and ACTD dossiers are prepared for the 30+ countries we export to. Here that file is not a submission requirement; it is what a permit officer and a tender evaluator each ask for on their own terms. It is also worth being precise about India's standing in the WHO framework, because it is commonly overstated. CDSCO appears on WHO's transitional listed-authority list with a scope of Vaccines. It is not listed for medicines. So any tender clause phrased as WHO-listed or maturity level 3 and above must be read carefully: a listing that satisfies it for vaccines does not carry a sterile injectable medicine. We would rather say that plainly than let a client find it inside a bid. Planning a Seychelles entry, or weighing a local importer against a regional pooled tender? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Seychelles for Global Buyers The regional layer is quieter than an Africa playbook would predict, and that is the finding rather than a gap. Seychelles both signed the African Medicines Agency treaty on 9 February 2020 and ratified it on 13 August 2020, and signature and ratification are not the same act. Neither currently imposes a marketing authorisation or supplies a reference list. It takes part in the SADC collaborative registration procedure only as a non-active member, and that procedure states it is not legally constituted. The donor layer is closed, and for a supplier that is the commercially important fact rather than a disappointment. Seychelles is high income on the World Bank's current classification, is absent from the Global Fund's 2026 eligibility list and sits outside Gavi's thresholds. It buys with its own money, which means the quality bar is set by the buyer in front of you and not by a funder's policy document. So the place to watch is probably not the national tender board. Much of the public volume now moves through the African Small Island Developing States pooled procurement initiative; WHO reports that Seychelles took its first consignment through it in 2024 and that a further cycle is being prepared. The first tender was floated on the United Nations Global Marketplace under WHO procurement rules, drew 37 bidders and produced six suppliers from five countries, India among them. Its eligibility criteria we could not obtain, and will not characterise. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register my injectable before it can be imported into Seychelles? No, because there is no product register. The Pharmacy Act of 1899, the Public Health Authority Act 2013 and the Public Health Act 2015 create no marketing authorisation, and the 2013 Act's registration provisions reach practices and premises rather than products. What is required is an import permit for the consignment, issued by the Trade Department on the approval of the Medicines Regulatory Unit. That Unit clears consignments; it does not issue marketing authorisations. Does Seychelles accept approval by India's CDSCO? Neither answer is available, and that is not evasion. Because Seychelles operates no product register, it publishes no list of trusted foreign authorities, so CDSCO is neither recognised nor excluded by name. Two provisions can be mistaken for such a list. The Pharmacy Act names pharmacopoeias, which are books rather than agencies, and an 1899 clause refers to a foreign medical academy while naming no agency. Neither is a reliance pathway. What are the registration fees and review timelines? There is no product registration, so there is no fee and no review timeline, and any number offered for either should be treated as invented. The costs that do arise attach to the consignment and the importer: the import permit, the local entity's business registration and licence, and the ordinary customs process. We are deliberately not quoting a permit fee, because the two sources we read disagree even about how long a permit lasts. Who buys injectables in Seychelles, and do I need a local partner? Public demand runs through the Health Care Agency and Seychelles Hospital alongside the regional pooled tender, and the import permit must be held by a Seychelles-registered importer and is non-transferable. We found no law requiring a foreign supplier to appoint a local agent, and will not claim the opposite. What is published and checkable: foreign bidders may join open international bidding but not open national bidding, and a margin of preference of up to 20 per cent may take account of association with local partners. Which injectable categories actually have demand there? Renal care is the clearest signal. Seychelles Hospital recorded 33,565 dialysis sessions in 2025 against 28,282 in 2023, with 245 patients on long-term dialysis, and the 2026 budget allocates SR 87 million to haemodialysis; the 2024 essential medicines list carries iron sucrose and the epoetins. Oncology is the second, with the hospital pharmacy doing its own aseptic cytotoxic reconstitution and carboplatin, cisplatin and paclitaxel listed as vials. One caution: the Ministry's own unit makes small-volume intravenous fluids, so basic fluids are not an open field. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Saint Lucia Last Updated: 19 September 2026 TL;DR: Saint Lucia has no product registration regime to file into. The Pharmacy Act registers pharmacists, pharmacies and sellers of poisons, not medicines, and the Ministry of Health's own profile with PAHO records marketing authorisation and import control as functions the country does not perform. There is therefore no recognition list and no dossier to win. The gate that decides public-sector volume is the OECS Pharmaceutical Procurement Service in Castries, whose prequalification asks for a GMP or ISO certificate and names no issuing authority. Key Takeaways The whole medicines statute is the Pharmacy Act, Cap. 11.21, enacted as Act 8 of 2003 and in force from 1 April 2003, with the Pharmacy (Forms and Fees) Regulations 2006 and the Pharmacy Regulations 2007 beneath it. All three are commenced, and on the face of the law as revised to 31 December 2022 the things they register are persons and premises. The absence of a product register is a proven absence rather than a gap in our searching. The joint Ministry of Health and PAHO pharmaceutical country profile states that legal provisions do not require marketing authorisation for pharmaceutical products on the market. That profile is dated January 2012, so read it as establishing the legal architecture, not today's administrative practice. Because there is no list of recognised reference authorities, asking whether India's CDSCO appears on one is a category error. CARPHA's regional system does publish such a list and India is absent from it, but Saint Lucia is not among the six CARICOM states with a legal marketing-authorisation requirement in the first place. The operative gate is the OECS Pharmaceutical Procurement Service, which the Pharmacy Act expressly carves out of the Pharmacy Council's remit. Its manufacturer prequalification form asks whether you hold GMP or ISO certification and names no issuing authority, and Indian manufacturers bid into those tenders in their own right. Introduction: What an Injectable Manufacturer in Saint Lucia Actually Has to Clear Most country guides for exporters begin by explaining how to register a product, and in Saint Lucia that framing fails immediately, because there is nothing to register with. Even the size of the market is contested: the World Bank gives 179,744 people for 2024 while the Central Statistical Office's 2022 census counted 172,948. We are not choosing between those figures, and a supplier building a volume forecast should not quietly choose either. The governing instrument is the Pharmacy Act, Cap. 11.21, which establishes a Pharmacy Council that registers pharmacists, pharmacies and authorised sellers of poisons. Its two subsidiary instruments deal with forms, fees, premises standards, storage and dispensing. None of the three creates a product register. Note what that does not mean: Saint Lucia is not an unregulated market. It has a pharmacy profession, licensed premises, a dispensing classification, poisons control and inspectors. What it lacks is product authorisation. What Sets a World-Class Injectable Manufacturer in Saint Lucia Apart What distinguishes a serious supplier is refusing to read an empty register as an open door. There is no marketing authorisation to obtain, which also means there is no regulatory asset to hold: no certificate, no data exclusivity, nothing to stop the next supplier following you in a month later. The absence of a registration procedure removes your cost of entry and your competitive moat in the same stroke, and it is not an affirmative legal permission to import. The second discipline is refusing to convert silence into a rule. Pharmaceuticals are not named in Saint Lucia's import-licensing schedules as notified to the WTO, but two catch-all entries sit in those schedules and we could not establish how they are applied to medicines in practice. So we will tell you what the schedules say and decline to tell you what happens at the wharf. Quality Systems Behind Every Batch Shipped to Saint Lucia Farbe Firma manufactures sterile injectables under WHO-GMP certification with ISO Class 5 aseptic filling in Gujarat, India, supported by in-house HPLC, GC, LAL endotoxin and Karl Fischer testing and ICH Q1A and Q1B stability programmes. Every batch ships with a certificate of analysis traceable to retained samples, and we prepare CTD and ACTD dossiers for the 30+ countries we export to. Here that documentation is not a filing requirement. It is the only independent quality evidence anyone in the chain will hold. That matters more here than in a market with a regulator to lean on. The 2012 profile records that Saint Lucia has no national quality control laboratory, no authority issuing good distribution practice licences and no manufacturers of its own. Where the state does not test what arrives, the manufacturer's analytical record is the whole of the assurance, and cold-chain integrity becomes a risk you carry rather than one an inspector catches. Weighing a Saint Lucia entry, or a pooled OECS tender against a private pharmacy channel? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Saint Lucia for Global Buyers The commercially useful fact is that the real gate is regional, not national. The Pharmacy Act provides that it shall not be construed as giving the Pharmacy Council responsibility over any activity for which the Pharmaceutical Procurement Service is responsible, and that Service is headquartered in Castries. Public procurement across the OECS is pooled through it, and suppliers must be prequalified and listed in its directory before they can bid. What that prequalification asks for is the part worth reading closely. The guidance requires products to meet WHO Good Manufacturing, Storage and Distribution Practice. The manufacturer form asks whether the company holds GMP certification, ISO certification or other, and says to attach the certificate. It names no issuing authority and publishes no list of trusted regulators. A WHO-GMP certificate from an Indian state licensing authority answers the question that form asks. The door has demonstrably been open. The most recent award schedule we could locate, covering 2015 to 2017, shows India-manufactured sterile injectables awarded across the pooled tender, among them bupivacaine, cefotaxime, amiodarone, labetalol, naloxone and iron sucrose. Indian manufacturers including Hetero Labs appear in the current cycles as opened and fully accepted for evaluation, which is bid admissibility and not an award; outcomes are unpublished, and we will not dress one up as the other. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register my injectable before it can be sold in Saint Lucia? There is no product registration procedure to enter. The Ministry of Health and PAHO country profile records that legal provisions do not require marketing authorisation for products on the market, and the Pharmacy Act as revised to 31 December 2022 adds none. Two cautions. That profile is dated January 2012, so it establishes the legal architecture rather than current practice. And no register is not permission to import: your counterparty, the border and any tender remain live gates. Is India's CDSCO on a recognised or reference authority list? The question is a category error here and we would rather say so than give a tidy yes or no. No Saint Lucian instrument we located names any foreign regulator at all, whether the US FDA, the EMA or CDSCO, because there is no reliance procedure for such a list to attach to. CDSCO is neither on a Saint Lucian list nor excluded from one, since exclusion presupposes a list. What are the registration fees and review timelines? There are none, because there is no product registration to charge for or to time. Any guide quoting a figure for Saint Lucia should be treated with suspicion. The fees that do exist under the Pharmacy (Forms and Fees) Regulations 2006 attach to pharmacists, sellers and premises rather than to products, and the one-year validity in the Act likewise attaches to a person's or premises' certificate, not to a product. Who actually buys, and do I need a local counterparty? Public-sector demand is pooled through the OECS Pharmaceutical Procurement Service in Castries, and the private channel runs through registered pharmacies and authorised sellers of poisons. Two routes into the OECS directory are visible in the published documents: a manufacturer may prequalify in its own right, or a prequalified distributor may carry you with letters of authorisation. In the 2015 to 2017 award list the contracting supplier is usually a regional distributor with the Indian firm named in the manufacturer column. What clinical demand should an injectables supplier actually plan for? A non-communicable disease profile. PAHO puts noncommunicable diseases at 82.1 per cent of deaths in 2019, with cardiovascular disease, diabetes and cancer leading, against adult hypertension of 27.1 per cent in 2015 and diabetes of 14.5 per cent in 2014. The population aged 65 and over is projected to rise from about a tenth in 2020 to 29.6 per cent by 2060, the fastest such rise in the Caribbean. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Samoa Last Updated: 18 September 2026 TL;DR: Samoa - the independent state, not American Samoa - has no operating medicines registration system, and the Ministry of Health says so in its own current policy: "No product evaluation, registration or listing system exists at the moment." What exists on the statute book is a narrow new-drug gate in the Drugs Act 1967. The real gates are the Essential Medicines List, a Central Warehouse contract, a Samoan importer, and Customs. Key Takeaways The Government of Samoa states in its National Medicines Policy and Plan of Action FY2023/24 - FY2027/28 that no product evaluation, registration or listing system exists. That is an absence quoted from the Ministry itself, not a "not found" on our side. Section 14 of the Drugs Act 1967 is unrepealed and does require approval before a "new drug" is imported. But "new drug" means a substance not previously used in Samoa, so an established generic injectable appears to sit outside it. The 90 days in section 14(3) is a standstill on sale, not an approval timeline. We found no Samoan list of recognised or stringent regulatory authorities. The closest text is a 2008 policy sentence naming authorities "such as TGA and FDA" - illustrative, not closed. India is unnamed, and nothing says Indian approval is refused. India's CDSCO appears on WHO's List of transitional WLAs, but the scope column designates it for vaccines only. A tender clause asking for a stringent authority for a medicine is not satisfied by CDSCO, and the Global Fund's definition excludes it too. Introduction: What an Injectable Manufacturer in Samoa Actually Has to Clear One clarification belongs at the top. Samoa here means the Independent State of Samoa, capital Apia, currency the Samoan tala. It is not American Samoa, a United States territory whose medicines are governed by the US FDA. Search results and health-statistics tables conflate the two constantly. A supplier who plans around American Samoan law plans around the wrong country's law. The second point is stranger. Most exporter guides explain how to register a product. For Samoa that framing has no object: the Ministry of Health's current National Medicines Policy and Plan of Action FY2023/24 - FY2027/28 states plainly that no product evaluation, registration or listing system exists at the moment, adding that Samoa applies reliance in the selection of medicines during procurement. Be precise about the evidential weight of that: it is not that we searched and found no register; the Ministry which would run one says there is none. What Sets a World-Class Injectable Manufacturer in Samoa Apart What separates a serious supplier here is refusing to over-read that vacuum, because there is law on the books. The governing instrument is the Drugs Act 1967, commenced 24 July 1967, revised as at 31 December 2023. It was the Food and Drugs Act 1967 until the Food Act 2015 removed the food references; older indexes carry the outdated title. Section 14 provides that no person may import or manufacture a new drug unless approved by the Chief Executive Officer of the Ministry of Health - not a chief pharmacist, not a medicines board. The definitional limit is the whole commercial point. A "new drug" is a substance which has not previously been used in Samoa. The trigger is novelty to the country, not to the supplier or the world, so a molecule already in Samoan use appears to fall outside section 14 altogether - a reading worth confirming with the Ministry rather than assuming. Note also what the section 14 dossier list does not ask for: no GMP certificate, no Certificate of Pharmaceutical Product, no bioequivalence, no site master file. Whether regulations under section 40 add any we could not establish either way. Quality Systems Behind Every Batch Shipped to Samoa Farbe Firma manufactures sterile injectables under WHO-GMP certification at ISO Class 5 aseptic filling in Gujarat, India, with in-house HPLC, GC, LAL endotoxin and Karl Fischer testing and ICH Q1A/Q1B stability work. Every batch ships with a certificate of analysis traceable to retained samples, and we prepare CTD and ACTD dossiers as standard for the 30+ countries we export to. The honest word in a Samoan context: nothing in Samoan law we could find requires a WHO-GMP certificate. It is a buyer-facing and donor-facing credential here, not a legal precondition. Documentation still matters. Samoa participates in the Pacific Medicine Testing Programme, under which Australia's Therapeutic Goods Administration laboratories test five products per country per year free of charge - post-market surveillance, not pre-market assessment. Meanwhile section 12 of the Drugs Act deems the person the label identifies as manufacturer or importer liable for a breach unless they prove otherwise. A supplier enters with no registration to shelter behind, judged by an Australian laboratory, carrying reverse-onus label liability. Planning a Samoa entry, or weighing a national route against a regional or donor-funded one? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Samoa for Global Buyers If entry is not rationed by dossier review, it is rationed by four other things, and those are where we put the effort. First, the Samoa Essential Medicines List, 4th Edition, July 2022, of about 170 medicines - a selection list, not a market authorisation. Second, the Ministry's Pharmaceutical Warehouse, opened in 2016 and also called the Central Warehouse, running on mSupply and procuring through framework contracts. Third, a Samoan importer or pharmacy supervised by a registered pharmacist. Fourth, Customs. The counterparty question is unusual and favourable. The Government states that it currently finances 100 per cent of the medicine needs of the public sector, so a supplier deals with a paying sovereign customer rather than a donor - though the same policy concedes it cannot pay suppliers on time, and states an intention to blacklist suppliers for untimely delivery. Donations from WHO, UNICEF, UNFPA and bilateral donors including China, India and Australia sit alongside that. We will publish no donor-versus-commercial split and no market size: the Government has not assessed its own market. Two structural facts read together. Samoa's policy quotes a World Bank assessment that Samoa, like all Pacific island countries, has little alternative other than to pay prices significantly above WHO median prices, and spends less on pharmaceuticals than its disease burden warrants. And the Government commits to using procurement to grow the Samoan private pharmaceutical sector. Both point the same way: partner with a local importer rather than sell around one. Local manufacture is no competing threat - local production is not on the agenda. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register my injectable product with a Samoan medicines authority? On the Government's own account there is no registration system to register with. The qualification is section 14 of the Drugs Act 1967, which still requires approval by the Chief Executive Officer before a new drug is imported - "new drug" meaning one not previously used in Samoa. For an established generic molecule that gate appears not to apply, but confirm it with the Ministry. Is India on a Samoan list of approved countries or recognised regulators? No such list was found in any Samoan instrument; we looked in the Drugs Act 1967, the Pharmacy Act 2007 and the Ministry's legislation index. The nearest text is a 2008 policy sentence about medicines "internationally recognized by authorities such as TGA and FDA" - note it names the US FDA, not New Zealand's Medsafe, and that "such as" makes it illustrative. India is unnamed, but absence from a non-exhaustive example is not exclusion. Does CDSCO approval count as a stringent or WHO-Listed authority for Samoa? Not for a medicine, and this is a trap we would rather you heard from us. CDSCO appears on WHO's List of transitional WLAs, but the scope column designates it for vaccines only; other authorities in the same table carry "Medicines" and India does not. Separately, the Global Fund's stringent-authority definition is limited to ICH members and observers before 23 October 2015, excluding CDSCO and leaving WHO prequalification or the Expert Review Panel. Neither Samoa nor India is a PIC/S member. What dossier format, fees and timelines should I budget for in Samoa? We can give no fee schedule, no review timeline and no prescribed dossier format, because none was found - a "not found" rather than a proven absence, partly explained by there being no registration procedure for a format to attach to. Never treat the 90 days in section 14(3) as an approval timeline: it is a standstill on sale, with no decision deadline and no deemed approval. We supply CTD and ACTD regardless. What should a sterile injectable supplier be most careful about in Samoa? Presentation design, and we say that with care rather than as a sales angle. Samoa's 2019 measles epidemic killed more than eighty people, most of them children under four; reported tolls differ by cut-off date, 81 as at 28 December 2019 against 83 in total, and we are not choosing between them. It followed a 2018 incident in which two children died after MMR was reconstituted with an expired anaesthetic instead of sterile water. The vaccine was cleared: the failure was handling at the point of care, not manufacture. Diluent pairing, labelling, look-alike vial risk and lot traceability are therefore matters on which a Samoan buyer may reasonably be exacting. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Sao Tome and Principe Last Updated: 18 September 2026 TL;DR: Sao Tome and Principe has no national product registration procedure to file into. The Ministry of Health's own Politica Farmaceutica Nacional 2019-2029 states the non-existence of procedures for the approval and registration of medicines, so there is no marketing authorisation to win and no recognition list. The operative gates sit elsewhere: the licensed local importer, customs, and for donor-funded volume the Global Fund quality assurance policy, which India's CDSCO credentials do not satisfy for a non-vaccine injectable. Key Takeaways The framework statute, Lei n.o 09/2018 (Lei Base de Saude), commenced 30 days after publication on 6 June 2018. Article 1(l) defines an Autoridade de Medicamentos but does not establish one, and Article 24 defers pharmaceutical activity to separate legislation we could not find. The absence of a product register is not an inference. The national pharmaceutical policy affirmatively records the non-existence of approval and registration procedures. That is a proven absence, unlike the many items below that we simply could not find. There is no recognised or reference authority list, so asking whether India's CDSCO appears on it is a category error. You cannot be omitted from a list that does not exist. For donor-funded volume the gate is the Global Fund quality assurance policy, not national law. Its stringent-authority test is closed to regulators that were ICH members or observers before 23 October 2015, and India's WHO transitional listed-authority entry is scoped to vaccines. Introduction: What an Injectable Manufacturer in Sao Tome and Principe Actually Has to Clear Most country guides for exporters open by explaining how to register a product. For Sao Tome and Principe that framing collapses at once, because the thing that would do the registering has not been built. The national pharmaceutical policy cites a population of 201,784 on a 2018 INE projection, a WHO AFRO profile gives roughly 219,160 for 2020, and later estimates run higher. We are not choosing between those figures, and neither should a supplier building a volume forecast. The governing instrument is Lei n.o 09/2018, the Lei Base de Saude, published on 6 June 2018 and in force roughly a month later. It repealed the 1980 Codigo Sanitario, the only instrument that had contained detailed pharmaceutical machinery, and replaced it with a deferral: Article 24 states that pharmaceutical activity has its own specific legislation, and Article 50 obliges the Government to issue implementing instruments. Whether any medicines decree has since been enacted we could not establish. That is a not found, not proof either way. What Sets a World-Class Injectable Manufacturer in Sao Tome and Principe Apart What distinguishes a serious supplier is refusing to read an empty register as an open door. There is no marketing authorisation to obtain, which also means there is no regulatory asset to acquire: no certificate, no data exclusivity, nothing stopping the next supplier following you in a month later. The absence of a registration procedure removes your cost of entry and your moat at once, and it is not an affirmative legal permission to import. The constraints that bite sit on the counterparty and the border. Pharmacy and establishment licensing runs through Decreto-Lei 53/78 and Article 47 of Lei 09/2018, which subjects private health units including pharmacies to State licensing. Customs duty is put at 5 to 10 per cent depending on product, with Ministry of Health imports excepted, and the ministry recommends making clearance faster, which implies it is not. What documents an importer must file at that border we could not establish, and we will not invent a checklist. Quality Systems Behind Every Batch Shipped to Sao Tome and Principe Farbe Firma manufactures sterile injectables under WHO-GMP certification with ISO Class 5 aseptic filling in Gujarat, India, supported by in-house HPLC, GC, LAL endotoxin and Karl Fischer testing and ICH Q1A and Q1B stability programmes. Every batch ships with a certificate of analysis traceable to retained samples, and we prepare CTD and ACTD dossiers as standard for the 30+ countries we export to. Here that documentation is not a filing requirement. It is the only independent quality evidence anyone in the chain will have. That matters because the policy is candid about the country's own capacity. Quality control is not carried out systematically, samples travel to external laboratories because there is no national quality control laboratory, and inspection is limited to documentary and visual checks. Pharmacovigilance still requires legal cover. Distribution does not meet good storage and distribution practice, particularly for thermolabile medicines, which argues for room-temperature-stable presentations where the molecule allows. Planning a Sao Tome and Principe entry, or weighing a national route against a regional or donor-funded one? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Sao Tome and Principe for Global Buyers The next question is whether a regional regime fills the national gap. It does not. Sao Tome and Principe is not an ECOWAS member, a point worth stating because it is often assumed. It is a founder of ECCAS, but we found no ECCAS medicines harmonisation instrument and no mutual recognition route; the literature describes ECCAS states as unharmonised. CPLP membership brings a cooperation aspiration in Article 12(3) of Lei 09/2018, not a pathway. The country appears on neither the signature nor the ratification list for the African Medicines Agency treaty, and the two are not the same. So the volume worth winning tends to flow through donor channels, where the rules are not Sao Tomean at all. A Global Fund malaria grant reported at around US$6 million is channelled through UNDP, so UN procurement rules and the Global Fund quality assurance policy govern eligibility. That policy requires WHO prequalification, authorisation by a stringent regulatory authority or WHO Listed Authority, or a time-limited Expert Review Panel recommendation. On the agency routes an Indian file fails twice over, and we would rather say so than let a client discover it inside a tender. The two reasons are independent and both easy to miss. The Global Fund's definition limits stringent authorities to those that were ICH members or observers before 23 October 2015, and CDSCO became a standing observer only in 2019. Separately, India's entry on WHO's published transitional listed-authority list carries the scope Vaccines, where Ghana, Nigeria and Tanzania are scoped Medicines. A non-vaccine injectable derives nothing from either. The honest conclusion is the inverse of the intuitive one: the investment that matters is WHO prequalification or an ERP pathway plus a licensed local importer, not a dossier with nowhere to go. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register my injectable before it can be sold there? There is no procedure to register into. The Ministry of Health's national pharmaceutical policy states in terms that procedures for approval and registration of medicines do not exist, and lists establishing them among its forward directives. This is one of the very few things here that is a proven absence rather than something we merely could not find. Read it carefully though: no register is not the same as permission to import, because the importer licence, customs and any ad hoc ministerial authorisation remain live and undocumented gates. Is India's CDSCO on a recognised or reference authority list? The question is a category error and we will answer it as one rather than give a tidy yes or no. There is no list of recognised or stringent authorities, because there is no registration procedure for reliance or abridgement to attach to. CDSCO is not on such a list, and equally has not been excluded from one, because exclusion presupposes a list. A named list does bite at the donor layer. What are the registration fees and review timelines? We found none, from any source, in either direction, consistent with there being no registration procedure to charge for. We will not publish a number we cannot support, and you should treat any guide quoting one with suspicion. The only monetary figures we located are a customs duty of 5 to 10 per cent depending on product, with Ministry of Health imports excepted, and fines in the repealed 1980 code. Neither is a registration fee. Who actually buys, and can I appoint a national distributor? The public sector is supplied through the Fundo Nacional de Medicamentos, created by Decreto-Lei 52/98, with a planned transformation into CAME. Whether that has happened we cannot say: the primary policy frames CAME as planned while a secondary page describes it in the present tense, and sources even differ on what the acronym expands to. We are not choosing. On the private side the policy records that pharmacies import for themselves because the country lacks a wholesale distributor company, so your counterparty is likely a single pharmacy or small importer, not a national distributor. In what language should labels and product information be supplied? Portuguese, for labelling and patient information. The policy requires INN presentation on packaging, labels, inserts and promotional material in Portuguese, and complains that dispensed products currently arrive without a Portuguese-language patient leaflet. What we will not tell you is that dossiers must be submitted in Portuguese, because we found no dossier procedure for a language rule to attach to. Two further cautions from the same document: the informal market is described as predominant, and donations other than one named project arrive without criteria safeguarding quality. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Barbados Last Updated: 16 September 2026 TL;DR: Barbados has historically had no product registration requirement at all - the gate is commercial, not regulatory: an importer's licence, supplier registration with the Barbados Drug Service, a local agent and a place on the national formulary. That is now changing: the Barbados Medical Products Act, 2026 was passed in June 2026 and will introduce marketing authorisation, but as of PAHO's July 2026 report the new Authority was not yet operating and its guidance was still in draft. Key Takeaways The Pharmaceutical Country Profile published by the Barbados Ministry of Health with PAHO/WHO - the most recent available, and dated 2011 - records that legal provisions did not require marketing authorisation for pharmaceutical products, and that no mutual recognition mechanisms were in place. What is required instead is an importer's licence, entry through authorised ports where products may be sampled, and GMP compliance by the manufacturer - including foreign manufacturers, though the same profile notes that Barbados does not publish its GMP requirements. The reference-authority list that actually bites sits one level up, at CARPHA's Caribbean Regulatory System, and India's CDSCO is not on it - but WHO prequalification is expressly an accepted route, and WHO PQ is open to Indian manufacturers. The Barbados Medical Products Act, 2026 creates a Barbados Medical Products Authority that will take over marketing authorisation. Enactment is not commencement, and the commencement position should be verified before anyone plans around it. Introduction: What an Injectable Manufacturer in Barbados Actually Has to Clear Barbados is a market of roughly 280,000 people, and it is one of the more unusual regulatory propositions in the Caribbean. Most country guides written for exporters open by explaining how to register a product. For Barbados that framing has historically been wrong, and an exporter who budgets for a registration dossier may be budgeting for the wrong thing while under-resourcing the thing that actually decides the outcome. According to the Pharmaceutical Country Profile published by the Ministry of Health with PAHO and WHO - the most recent such profile available, and dated 2011 - Barbados did not require marketing authorisation, or product registration, for pharmaceutical products placed on its market, and no mutual recognition mechanisms were in place. It lists inspection, import control, licensing and quality control as functions the authority did perform. We flag the date deliberately: fifteen years is a long time, and a new Act has since passed. What Sets a World-Class Injectable Manufacturer in Barbados Apart If there is no dossier queue, what is there? On the evidence, a sequence: a licensed Barbadian importer; the manufacturer registered as a supplier with the Barbados Drug Service; a local agent, because the country profile records that international companies are required to bid through one; the product listed on the Barbados National Drug Formulary, some seven hundred medicines selected by a Drug Formulary Committee advisory to the Minister; and then success in a Drug Service competitive tender. Note the noun carefully - companies are registered with the Drug Service, not products. Conflating supplier registration with product registration is the single commonest error in this market. Two features of that tender reward a manufacturer who can document itself. The profile records that a process exists to ensure the quality of products procured for the public sector, including prequalification of both products and suppliers, and that medicines are tested for public procurement prequalification - but not for product registration, which neatly locates where the real quality gate sits. It also records that there are no legal provisions giving priority to locally produced goods, which is favourable to an importer, and that at the time of writing 97.25 per cent of pharmaceuticals were supplied by foreign companies registered with the Drug Service. Quality Systems Behind Every Batch Shipped to Barbados Farbe Firma manufactures sterile injectables under WHO-GMP certification at ISO Class 5 aseptic filling, with in-house HPLC, GC, LAL endotoxin and Karl Fischer testing and ICH Q1A/Q1B stability programmes, and every batch ships with a certificate of analysis traceable to retained samples. That matters more here than in a registration market, because Barbados has no national quality-control laboratory of its own: the country profile records that testing is contracted out, naming the Caribbean Regional Drug Testing Laboratory and Experchem in Canada. One requirement clearly does reach a foreign manufacturer. The profile records legal provisions requiring manufacturers, domestic and international alike, to comply with Good Manufacturing Practices - while noting in the same passage that GMP requirements are not published by the government. In practice a real obligation is measured against an unpublished standard, so the applicable expectation has to be established in dialogue with the Barbados Drug Service, and a supplier arriving with WHO-GMP certification and a complete site master file is arguing from a much stronger position than one who is not. Planning a Barbados entry, or weighing a national route against a regional or donor-funded one? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Barbados for Global Buyers The lesson the Caribbean teaches repeatedly is that when the national gate is open, the exclusion is usually one level up. Barbados has no national list of recognised regulators, because it has had no registration system to attach one to. But a named reference-authority list does exist regionally, and an Indian manufacturer will meet it: CARPHA's Caribbean Regulatory System conducts abbreviated review only for products already approved by a designated reference authority - the PAHO regional reference authorities, the European Union or the United States - and India is not among them. There is, however, an explicit way through, and it is the most commercially important sentence we can offer. CARPHA lists WHO prequalification alongside those agencies as a qualifying basis for review, and WHO prequalification is fully open to Indian manufacturing sites. Two honest limits belong with it: CARPHA's review is confined to products on the current WHO Essential Medicines List or the PAHO Strategic Fund list, and CARPHA only recommends favourably reviewed products to member states for consideration, leaving the decision national. The forward-looking picture matters just as much. PAHO reported on 30 July 2026 that, following the passing of the Barbados Medical Products Act in mid-June, officials were working on draft guidance for product registration, draft accompanying regulations, staffing and systems for the new Authority, and had explored the use of reliance and recognition approaches. A Barbadian list of trusted regulators may well emerge from that work. None has been published, and which authorities will appear on it is not known - including to Barbados. What we can do is have a WHO-GMP file, a CTD/ACTD dossier and a prequalification pathway ready for the moment it is. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register my product with a Barbados medicines agency? Historically, no - what is required is an importer's licence, with entry through authorised ports where products may be sampled and inspected. The caveat is important: the Barbados Medical Products Act, 2026 will introduce marketing authorisation under a new Authority, which as of July 2026 was not yet operating. Confirm the current position before you commit. Is India on any Barbados list of approved source countries? There is no such Barbadian list, because there has been no registration system to attach one to. At regional level there is a list and India is not on it: CARPHA's Caribbean Regulatory System names the PAHO reference authorities, the EU and the USA. CDSCO approval alone therefore does not unlock the CARPHA route, and it is worth adding that India's CDSCO appears on WHO's transitional listed-authority list with scope limited to vaccines, so a "stringent authority" argument built on it will not survive scrutiny for a non-vaccine injectable. Will WHO Prequalification actually help me in Barbados? For the CARPHA route, demonstrably yes - CARPHA expressly lists WHO prequalification alongside the reference agencies as a qualifying basis for abbreviated review, and that is the documented mechanism by which a product approved in India can enter the CARICOM abbreviated pathway. Whether Barbados itself gives WHO PQ any standalone weight is not documented, and since Barbados has had no registration system the question may not yet be a meaningful one. What dossier format is required, and do I need a WHO CPP? We found no Barbadian instrument prescribing CTD, ACTD or eCTD, and none requiring a WHO Certificate of a Pharmaceutical Product. That is a "not found" rather than a proven absence, and it is partly explained by there being no registration procedure yet to prescribe a format. Expect it to be settled by the draft guidance PAHO reports is being prepared. We could not establish which pharmacopoeias Barbados recognises, and we would not assume BP merely from the legal heritage. How do I find current Drug Service tenders and supplier registration forms? Directly, unfortunately. Throughout our research the Barbados Drug Service website was returning a server error rather than a page, so current tender documents, supplier registration forms, formulary editions and volumes could not be obtained from published sources. Prospective suppliers will need to approach the Drug Service and the Ministry of Health and Wellness directly. Note also that Barbados operates a general import licensing system under the Miscellaneous Controls Act Cap. 329 administered by the trade ministry, separate from any health requirement. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Vanuatu Last Updated: 16 September 2026 TL;DR: Vanuatu does not appear to operate pre-market product registration for medicines. The Sale of Medicines (Control) Act [CAP 48], as amended in 2014, regulates who may import and wholesale rather than which products may be sold, and the decisive check is a post-arrival release decision by the Principal Pharmacist. The practical gate is therefore your Vanuatu counterparty and the quality file you hand them, not a dossier queue. Key Takeaways The governing instrument is the Sale of Medicines (Control) Act [CAP 48], commenced in 1966 and substantially amended by Act No. 8 of 2014, which came into force on 17 July 2014. We found no pre-market registration requirement and no published list of recognised foreign regulators or approved countries of origin. That is a "not found", not a proven absence, and it should be confirmed with the Ministry of Health rather than assumed. Section 3A is the provision that matters: Customs records each importation and sends the list to the Principal Pharmacist, who may approve or refuse release and may attach conditions - a check that can happen after your goods have landed. Vaccines are a separate channel entirely, running through the UNICEF Vaccine Independent Initiative pooled mechanism, where UNICEF's supplier rules apply rather than Vanuatu's import route. Introduction: What an Injectable Manufacturer in Vanuatu Actually Has to Clear Vanuatu is a market of roughly 330,000 people spread across some eighty islands, and that geography shapes its medicines supply more than any single regulation does. For an exporter the first question is usually "what do I have to register, and with whom?" In Vanuatu that question has an unusual answer, and getting it wrong in either direction is expensive - a supplier who assumes a heavy registration regime will price in work that may not exist, while one who assumes no control at all will meet section 3A at the wharf. The operative instrument is the Sale of Medicines (Control) Act [CAP 48], first commenced in 1966 and substantially amended by Act No. 8 of 2014, in force from 17 July 2014. Read on its face, that Act regulates persons and premises rather than products. It sets out who may import and wholesale medicine; it does not establish a marketing authorisation, prescribe a dossier, or name a single foreign regulator. Vanuatu's own National Medicines Policy 2015-2020 describes it as "an aspiration" that medicines used in the country should be registered - language a government does not use about a system it already runs. What Sets a World-Class Injectable Manufacturer in Vanuatu Apart What separates a serious supplier here is knowing which door actually opens. Under section 3(1), a person intending to be a wholesale supplier of medicine must first obtain the prior written approval of the Pharmacists Practitioners Commission, and under section 3(2) an approved wholesaler may supply only a licensed medical practitioner, pharmacist, licensed dentist, licensed veterinarian, or a person approved by the Minister by Order. The gate is the counterparty. An exporter without an approved Vanuatu wholesaler has no route in, however good the product is. Then comes section 3A, which is where careless shipments come undone. The Director of Customs records each importation of medicine for sale and forwards the list to the Principal Pharmacist, who may approve or refuse the release of those medicines, must give reasons for a refusal, and may attach conditions to any approval. That is a discretionary power exercised on goods that have already travelled. The way to make it straightforward is to arrive with a file that answers the obvious questions before they are asked, rather than to argue about them from a container yard. Quality Systems Behind Every Batch Shipped to Vanuatu Farbe Firma manufactures sterile injectables under WHO-GMP certification at ISO Class 5 aseptic filling, with in-house HPLC, GC, LAL endotoxin and Karl Fischer testing, and stability studies run to ICH Q1A and Q1B. Every batch ships with a certificate of analysis traceable to retained samples. We prepare CTD and ACTD dossiers as standard, and we can supply a WHO-format CPP on request - not because Vanuatu's statute demands one, but because it is the document that makes a discretionary release decision easy for the person making it. Two points deserve an honest word rather than a sales one. First, Vanuatu's National Medicines Policy gives priority in public procurement to medicines prequalified by WHO, with current WHO-scheme certification as the stated fallback - but that is a procurement policy, not a statutory import condition, and it was written for the period 2015-2020. Second, India's CDSCO appears on WHO's transitional WHO-Listed Authority list with its scope limited to vaccines, so no Indian supplier should present CDSCO as a listed authority for medicines generally. We would rather tell you that than let you discover it in a tender. Planning a Vanuatu entry, or weighing a national route against a regional or donor-funded one? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Vanuatu for Global Buyers The most expensive error in a Pacific file is not a technical one. It is assuming that because a national gate is open, there is no gate at all. Vanuatu's national route appears genuinely permissive on the face of the statute, and we have found nothing excluding Indian-manufactured medicines from it. But the same is not automatically true of every channel that supplies the country, and treating the three as one is how suppliers lose a year. So we separate them. National law asks who you sell through and whether the Principal Pharmacist will release the consignment. Public-sector supply is a different question: procurement is limited to Vanuatu's Essential Drug List and runs through the Central Medical Store under Ministry of Finance procurement guidelines, using bulk contracts, standing offer agreements with preferred suppliers, and requests for quotation. The contract references the Ministry publishes date from 2016-2018, so current arrangements have to be confirmed directly rather than read off a website. Vaccines are a third question again. Vanuatu obtains them through the UNICEF-managed Vaccine Independent Initiative, a pooled mechanism covering eleven Pacific island countries, which means a vaccine supplier must satisfy UNICEF Supply Division's own qualification rules - a channel that can exclude a supplier the national route would admit. What we offer is not a promise that every door is open, but a clear account of which is which, a dossier built to the format each one expects, and the batch documentation to survive scrutiny at any of them. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register each product with the Ministry of Health before importing? We found no pre-market product registration requirement in Vanuatu law. CAP 48 as amended in 2014 regulates who may import and wholesale, not which individual products are approved, and the National Medicines Policy 2015-2020 still describes registration as an aspiration. Treat that as "no requirement found" rather than "confirmed no requirement": not every Order made under section 7 was accessible to us, and the Principal Pharmacist can attach conditions to any consignment. Confirm with the Office of the Principal Pharmacist before you ship. Is India on a Vanuatu list of approved countries or recognised regulators? No such list was found, and no legal instrument creating one was found either. There is therefore no basis for saying Indian-manufactured medicines are excluded - and equally none for saying they are formally recognised, because there appears to be nothing to be recognised by. That is an open question to put to the Ministry of Health, not a settled position in either direction. What dossier format does Vanuatu accept - CTD, ACTD or eCTD? No instrument prescribing any dossier format was found, which is unsurprising given that no registration route was found for a format to attach to. We supply CTD and ACTD as standard because they travel well across the region and because a well-organised file is what makes a section 3A release decision quick. We would not tell you Vanuatu requires CTD, because we have seen nothing that says so. Is a WHO-GMP certificate and a CPP enough to clear customs? For public tenders, the National Medicines Policy puts WHO prequalification first and current WHO-scheme certification second, so a CPP addresses the stated policy expectation. For private commercial import we found no statutory CPP requirement. Neither document is a legally sufficient condition, because the release decision under section 3A is discretionary - but carrying both is the practical way to make that decision uncontroversial. How large is the India-Vanuatu pharmaceutical trade? We cannot give you a reliable figure, and we would rather say so than pick one. The UN COMTRADE series as republished by aggregators ends in 2011 at about US$2.14 million, while mirror data reported from the Indian side has been quoted at around US$1.11 million for 2024. Those are different reporters, different years and different directions of a mirror pair, and we are not in a position to reconcile them. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in the Bahamas Last Updated: 15 September 2026 TL;DR: The Bahamas has no product registration or marketing authorisation regime for medicines. The Pharmacy Act, 2009, consolidated as Chapter 227, runs to 52 sections and creates no drug register and no dossier assessment. What it creates instead is a pharmacopoeia standard and a premises-and-person licensing system run by the Bahamas Pharmacy Council. The Bahamas National Drug Agency is a procurement unit of the Public Hospitals Authority, not a regulator. Farbe Firma Pvt Ltd manufactures over 100 sterile injectables under WHO-GMP in ISO Class 5 cleanrooms in Gujarat, India, releases to USP and BP specifications, and supplies more than 30 countries. Key Takeaways There is no Bahamian marketing authorisation to obtain. The Pharmacy Act Chapter 227 contains no register of medicinal products, and the Pharmacy Council's published fee schedule contains no product registration fee of any kind, which corroborates the absence rather than merely asserting it. Section 27(1) is the real list, and it names pharmacopoeias rather than authorities: the British, United States, European and International Pharmacopoeias, plus any other approved by the Minister. The Indian Pharmacopoeia is not among the four named, and no instrument adding it was found. The practical gate is a Bahamian counterparty: a Pharmacy Council registered warehouse and a wholesale distributor licence, each valid one year, with import and export governed by the Customs Management Act. The lists that do exclude India belong to CARPHA's Caribbean Regulatory System and to PAHO-funded procurement, not to Bahamian law. CDSCO appears on neither, and its WHO transitional listing is scoped to vaccines rather than medicines. Introduction: What an Injectable Manufacturer in the Bahamas Actually Has to Clear The Bahamas is a high-income market of 403,033 people on World Bank 2025 data, with GNI per capita of USD 37,020 in 2024 and current health expenditure of USD 2,262 per capita, 6.3 percent of GDP, in 2023. Out-of-pocket spending is 27.5 percent and life expectancy is 74.7 years in 2024. Non-communicable disease carried 73.1 percent of total deaths in 2019, with a 20.3 percent probability of premature death between ages 30 and 70. There is no domestic manufacturing base to displace. Competition is on price, reliability and shipping rather than on dossiers. That last point is not a figure of speech. The governing statute is the Pharmacy Act, 2009, Act No. 8 of 2009, consolidated as Chapter 227 and most recently republished as the LRO 1/2017 edition. Its Arrangement of Sections runs from section 1 to section 52 and covers the Pharmacy Council, registration of pharmacies, registration and licensing of pharmacists and technicians, discipline, the sale and administration of drugs, the standard and importation of drugs, poisons, prescriptions, registration of factories and warehouses, and licensing of manufacturers and wholesalers. Nowhere in it is there a register of medicinal products, a marketing authorisation, or a dossier assessment. A Pharmacy (Amendment) Act 2013 exists, but the government PDF returned no machine-readable text, so we do not describe what it changed. What Sets a World-Class Injectable Manufacturer in the Bahamas Apart Where there is no dossier to file, the differentiator moves to the specification and the counterparty. Section 27(1) requires every drug manufactured, offered for sale, imported or exported to meet one of the British Pharmacopoeia, the United States Pharmacopoeia, the European Pharmacopoeia, the International Pharmacopoeia, or any other pharmacopoeia approved by the Minister, with breach an offence carrying a fine of up to twenty thousand dollars. The Indian Pharmacopoeia is not among the four named. It could in principle enter through the Ministerial limb, but no instrument doing so was found, and no comprehensive index of orders made under the Act was located, so the position is not-found rather than proven-absent. This is a soft constraint for a manufacturer that plans for it, and a hard one for a manufacturer that does not. Farbe Firma releases to USP and BP specifications as a matter of routine, which satisfies section 27 directly and removes the question. The second half of the gate is sections 33 to 36: no person may import drugs for storage and wholesale distribution unless the warehouse is registered with the Bahamas Pharmacy Council, with penalties up to fifteen thousand dollars, and the Council separately licenses manufacturers and wholesale distributors. Both the premises certificate and the licence are valid for one year. The Council's published Second Schedule sets warehouse registration at 2,000 dollars with renewal at 1,000, and a wholesale distributor licence at 500 with renewal at 250. Import and export themselves are governed by the Customs Management Act. Quality Systems Behind Every Batch Shipped to the Bahamas Farbe Firma manufactures more than 100 sterile injectables at a WHO-GMP certified facility in Gujarat, India, with aseptic filling in ISO Class 5 environments and supply into more than 30 countries. The same quality system that supports our CTD and ACTD dossiers in registration markets supports a Bahamian consignment where no dossier is filed: validated aseptic process simulations, routine environmental monitoring, HPLC and GC assay and related-substance methods, Karl Fischer moisture determination, LAL bacterial endotoxin testing, container closure integrity testing, and ICH Q1A stability programmes with photostability under ICH Q1B. Stability deserves a precise statement rather than a confident one. WHO's stability-conditions table, in its March 2021 update, carries the Bahamas at 30 degrees Celsius and 65 percent relative humidity. The entry is bracketed and footnoted, which in WHO's own key means it was supplied by the IFPMA from climate literature rather than confirmed by a Bahamian regulator, and WHO states a condition rather than a zone label. India's own entry in the same table is 30 degrees Celsius and 70 percent relative humidity and is marked as officially confirmed. Indian long-term data therefore meets or exceeds the condition attributed to the Bahamas, which is a useful fact and one we are careful not to overstate into a Bahamian requirement that no Bahamian instrument has ever set. Planning a Bahamas supply line or a wider Caribbean entry? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in the Bahamas for Global Buyers The absence of a registration regime is an opportunity and a discipline at the same time. There is no dossier moat protecting an incumbent, so a new supplier can move quickly. But there is also no regulatory review standing between a buyer and a bad batch, which means the buyer's own diligence carries the whole load. That is precisely the situation in which a WHO-GMP certificate, a genuine ISO Class 5 aseptic operation, batch-level certificates of analysis and an auditable stability file stop being paperwork and start being the entire basis of trust. We would rather be bought on that basis than on price alone. It is equally important to be honest about what an Indian file cannot reach. CARPHA's Caribbean Regulatory System is reliance-gated: it recommends only products already authorised by a listed reference authority, or WHO-prequalified, and CDSCO appears on no such list. PAHO-funded procurement applies the same test, admitting WHO Prequalification, stringent regulatory authorities or the Americas-only national authorities of regional reference. CDSCO's WHO transitional listing, in the December 2025 version, is scoped to vaccines and not to medicines. Neither the Bahamas nor India appears on any of the four PIC/S lists, including former pre-applicants. And India's own bilateral record for the Bahamas names four instruments, on foreign office consultations, bilateral cooperation, tax information exchange and visa exemption, with nothing on pharmaceuticals, GMP recognition or pharmacopoeia recognition. The Indian Pharmacopoeia Commission's own recognition list, updated 10 July 2026, names twenty-five countries including nine in the Caribbean and Latin America; the Bahamas is not among them. Two structural facts frame the commercial reading. The Bahamas is a full CARICOM member but does not participate in the CARICOM Single Market and Economy, and it is a World Trade Organization observer rather than a member, with an accession pending since 2001 and resumed in 2017. Neither fact blocks supply, but both mean regional shortcuts arrive here later than elsewhere, and that the practical route runs through a licensed Bahamian wholesaler and, for public volume, through tender. That is the route we build with partners: correct pharmacopoeial specification, a licensed counterparty with a registered warehouse, English labelling, and a stability file that already exceeds the condition WHO attributes to the islands. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register a medicine in the Bahamas before importing it? No Bahamian product registration or marketing authorisation was found. The Pharmacy Act Chapter 227 creates no drug register and no dossier assessment, and the Pharmacy Council's fee schedule contains no product registration fee. What is required is that the product meets a section 27 pharmacopoeia and that the importer holds a Council registered warehouse and a wholesale distributor licence. We state this as no such regime found rather than as a regime confirmed absent by the regulator. Does the Bahamas National Drug Agency approve medicines? No, and this is the most common error made about the Bahamian system. The BNDA was formed in 1994 to streamline purchasing for public sector health facilities and now sits under the Public Hospitals Authority as a shared service unit. Its listed functions are supply management and tendering, pharmacy policy, training and narcotic records. No marketing authorisation, dossier assessment, GMP inspection or pharmacovigilance function is listed. It is also a different body from the Bahamas National Drug Council, which works on substance abuse. Is the Indian Pharmacopoeia accepted in the Bahamas? Not among the four pharmacopoeias named in section 27(1), which are the British, United States, European and International Pharmacopoeias. Section 27(1)(v) allows the Minister to approve another pharmacopoeia, but no instrument doing so was found and no comprehensive index of orders under the Act was located. In practice this is straightforward to work around: Farbe Firma releases to USP and BP specifications, which satisfies section 27 directly. How does an Indian supplier reach public-sector volume in the Bahamas? Through tender rather than registration. The BNDA's remit expressly includes tendering exercises for the public hospitals. Separately, the National Health Insurance (Specified Chronic Diseases) (Prescription Drug Fund) Act 2025 was assented and gazetted on 28 August 2025 and would move the national prescription drug plan from the National Insurance Board to the National Health Insurance Authority, allowing contracts with international suppliers under the Public Procurement Act 2023. Its section 1(2) provides for commencement on a date appointed by the Minister, and we could not confirm that the notice has issued, so this should be treated as pending rather than in force. We did not locate a current tender portal or supplier prequalification document and make no claim about how to register as a supplier. Does a CARPHA or PAHO route help an Indian injectable manufacturer here? Not on a CDSCO-only file. CARPHA's Caribbean Regulatory System issues recommendations rather than authorisations and accepts only products already authorised by a listed reference authority or WHO-prequalified; CDSCO is on neither list and WHO-GMP is not an eligibility route. PAHO-funded procurement applies the same reliance test. WHO's April 2022 account describes technical support to establish a Bahamian fast approval pathway recognising CRS recommendations in the future tense, and we found no instrument completing it in the years since, so we treat it as an open watch item rather than an available route. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. Email director@farbefirma.org. Request a Quote / View Products / Blog